TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05732363

Intervention type: DEVICE
Intervention: Ultrasonography
Description: The US muscle measurement will be performed with the handheld portable Philips Lumify Sonography connected to a Samsung tablet. The measurement will take approximately 5-10 minutes. A seven-point measurement has to be performed based on the seven-site Jackson Pollock Generalized Prediction Equations for circumference and skinfold thickness measurements.6,7

Intervention type: RADIATION
Intervention: Dual-energy X-ray Absorptiometry
Description: The brand of the DXA scanner is the Hologic Discovery A, which has a weight limit of 204 kilograms. During the DXA scan, patients will be exposed to radiation, which is approximately 0.2 micro Sievert (µSv) for measuring body composition. For comparison: the average amount of background radiation per hour is approximately 0.23 µSv. The DXA body composition scan will be performed according to standard protocol by a specialized technician.
Study: NCT05839470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cadonilimab (6mg/kg, iv, Q2W, Day1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m² iv continue for 2 hours,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin or levoleucovorin
Description: leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m² cont. inf. 46h
Study: NCT05057702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized Tumor Board Treatment Plan
Description: Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by PNOC specialized tumor board
Study: NCT06475924

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Caesarean scar defect evlauation by ultraosund
Description: Women will be examined in the lithotomy position with an empty bladder. The uterus will be examined in a standardized way excluding causes of abnormal uterine bleeding or pelvic pain (myoma, polyp, pelvic inflammatory disease, adenomyosis).~Upon detection of the SCD, the following will be measured:~In the midsagittal plane: the depth (the vertical distance between the base and apex of the defect), width (the length of the widest gap along the cervicoisthmic canal), residual myometrial thickness (RMT) overlying the defect, and the adjacent myometrial thickness fundal to the defect.~In the transverse plane: the length of the defect.~The uterine position will be classified as anteverted or retroverted.~Clinical symptoms of the patients will be reviewed such as :Postmenstrual spotting, Abnormal uterine bleeding, Pain, Secondary infertility.
Study: NCT06215976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin 500mg tablets twice daily
Study: NCT05246293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib in doses of 5 mg BID, in RA-ILD patients at stable doses of prednisone ≤ 10 mg/day during the last three months.~Patients who met the inclusion criteria of the study protocol will received tofacitinib 5 mg BID for 12 months
Study: NCT04988464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Scholar
Description: A single-session, internet-based insomnia intervention for college students

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Building Healthy Habits
Description: A single-session, self-guided, internet-based intervention focused on healthy eating and exercise
Study: NCT05378724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospital Fit 2.0, HFITAPP0, release 05, Maastricht Instruments B.V., the Netherlands
Description: Hospital Fit consists of a smartphone app combined to the MOX accelerometer. Hospital Fit provides patients and physiotherapists direct feedback on patients' physical activity behavior. Individual goals regarding the number of minutes per day spent walking can be set by the therapist. Hospital Fit also gives patients insight into their own recovery process. During every treament, the physiotherapist will evaluate the extent of functional recovery. In addition, Hospital Fit will give physiotherapists the option of creating a patient-specific exercise program supported by videos. During every treatment session, the patient and physiotherapist will evaluate (and if necessary adapt) the amount of activity performed since the previous treatment, the extent of functional recovery and the exercise program.
Study: NCT06102434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Five oral capsules containing 5 mg of psilocybin each
Study: NCT04960917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of ehealth literacy workshop
Description: Intervention components will include a three session workshop, enabling participants to raise their knowledge of the different available health resources and how to find them, their ability to determine which health resource is reliable, their ability to use the health information online to make health decisions, their knowledge of the online services offered by HMOs/Ministry of Health, and their ability to navigate HMO and preform actions such as set an appointment, find a doctor, and find contact information
Study: NCT05884190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Medical Model (RMM)
Description: Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Medical Model (RMM)
Description: Remote home blood pressure (BP) monitoring once a day for the first 7 days and then at least weekly or more frequently as per a standardized blood pressure protocol up to six weeks and weekly virtual visits for 6 weeks and up to 12 weeks as needed by a physician extender (e.g. Nurse Practitioner, Pharmacist, etc.), and screening for social determinants of health and anxiety/ depression with referral for services if positive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Model (CHM)
Description: Utilization of community health workers trained in a strength-based trauma informed dyadic evidence-based approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: SoC for Postpartum Hypertension

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: SoC for Postpartum Hypertension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SoC
Description: SoC for Postpartum Hypertension
Study: NCT05200663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tab Tamoxifen 10 mg
Description: Tablet tamoxifen 10mg twice a day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tab Tamoxifen 10mg,Cap vitamin E 400mg
Description: Tab tamoxifen 10 mg is given twice a day and cap vit E 400mg is given once a day for 6 months
Study: NCT06062277

Intervention type: DRUG
Group type: OTHER
Intervention: Colchicine 0.5 MG
Description: one oral tablet daily for 30 days
Study: NCT04825535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard psychiatry and cognitive behavioral online intervention
Description: The cognitive behavioral online intervention has been assessed in a prior trial. Ritvo, P, Knyahnytska, Y, Pirboglou, M, Wang, W, Tomlinson, G, Zhao, H, Linklater, R, Kirk, M., Katz, J., Harber, L., Daskalakis, ZJ An online mindfulness-based cognitive behavioural therapy intervention for youth diagnosed with major depressive disorders: J Med Internet Res 2021, Mar 17; 23 (3), e24380

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatry and cognitive behavioural in-person intervention
Description: The effectiveness of standard care office-based group CBT-MM at CAMH is indicated in a past study (n = 119) where depression symptoms reduced (after 16 weeks treatment) by 27% \[3,18 \]. The office-based groups follow a carefully conceived structure that centers on the workbook Mind Over Mood (MOM) (Guilford Press) \[41\]. Key CBT concepts and procedures are conveyed via work sheets that structure personal and group exploration.
Study: NCT05572723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2 MG
Description: Remifentanil is an opioid; it has sedative, analgesic, and sympatholytic properties.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Studies show that dexmedetomidine is superior to currently commonly used remifentanil in terms of intraoperative blood pressure control and postoperative pain.~Dexmedetomidine, an alpha-2-adrenoceptor agonist, has sympatholytic, sedative, anesthetic, analgesic, and vasoconstrictor effects. It lowers blood pressure by decreasing plasma norepinephrine and epinephrine levels, thereby reducing intraoperative bleeding. Dexmedetomidine is defined as an analgesic that is now widely used to induce and maintain anesthesia and to control postoperative pain, and is defined as an analgesic that does not cause respiratory depression and neurocognitive impairment. Many studies have shown that the use of perioperative dexmedetomidine reduces the stress response to anesthetic induction and surgery and provides hemodynamic stability.
Study: NCT06030583

Intervention type: OTHER
Intervention: Scales and Forms
Description: This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.

Intervention type: OTHER
Intervention: Scales and Forms
Description: This study does not involve any interventions. Information will be collected from the study group and the control group through scales and forms.
Study: NCT06554405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral Intervention
Description: Treatment plan will be applied to the symptomatic side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral Intervention
Description: Treatment plan will be applied to the symptomatic and nonsymptomatic sides.
Study: NCT06537193

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMRI
Description: The study subjects will receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination will be conducted using a 3-Tesla MRI machine, and the MRI protocol consists of T2-weighted imaging,diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
Study: NCT05593458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin by arterial infusion plus S-1
Description: 3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX neoadjuvant
Description: 3 cycles of SOX neoadjuvant chemotherapy every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab neoadjuvant
Description: 3 cycles of neoadjuvant immunotherapy every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab neoadjuvant
Description: 3 cycles of neoadjuvant immunotherapy every 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy plus D2 lymph node dissection
Description: All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy plus D2 lymph node dissection
Description: All patients, whose lesions are resectable and medically operable after 3 cycles neoadjuvant chemotherapy, will receive gastrectomy plus D2 lymph node dissection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX adjuvant, Sequential S-1
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX adjuvant, Sequential S-1
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab adjuvant
Description: 3 cycles of adjuvant immunotherapy every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab adjuvant
Description: 3 cycles of adjuvant immunotherapy every 21 days.
Study: NCT06381843

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (Sf9 Cell)
Description: 1dose, Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: 1dose, Intramuscular Injection
Study: NCT04705584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone (as Acetate)
Description: Standard treatment protocol includes Topical steroids for 8 weeks with gradual dose tapering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic Suspension
Description: This treatment arm includes the use of topical cyclosporine A after 2 weeks of topical steroid use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTacrolimus Topical
Description: This treatment arm includes the use of topical Tacrolimus after 2 weeks of topical steroid use.
Study: NCT04978779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152
Description: Weekly IV infusion for 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIP152
Description: Weekly IV infusion for 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTKi
Description: Taken per local prescribing information
Study: NCT04462172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNS
Description: perform preoperative preparation, intraoperative operation and internal fixation implantation according to the instructions provided in the product packaging.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: three cancellous screws with an inverted triangle pattern are used to fix the fracture of femoral neck.
Study: NCT04826731

Intervention type: OTHER
Intervention: Incentive Spirometer/Respiratory Exerciser
Description: A patient is considered acceptable for the Incentive Spirometer Group if the patient can use an incentive spirometer and/or a respiratory exerciser at least four times per day. A pulmonary medicine specialist will confirm the proper usage of the device.
Study: NCT05502887

Intervention type: DIAGNOSTIC_TEST
Intervention: Sublingual in vivo microscopy with the Glycocheck microscope
Description: For the collection of longitudinal microscopy data, sublingual in vivo microscopy with the Glycocheck microscope will be performed at the following timepoints: 2-3 x between day (D) -28 of allogeneic HSCT or CAR T cell therapy and before start of the conditioning regimen, once between D2-D14, once between D15-28, once between D30- D100 and at the onset of endothelial complications such as acute GvHD, TMA, sepsis, VOD and IPS following allogeneic HSCT or CAR T cell therapy. Sublingual microscopy requires 15-30 minutes and is similar to sublingual temperature measurement. To this extent, a tube with a diameter of approximately 1cm carrying a microscope at the tip is inserted into the mouth and under the tongue to measure endothelial structures (blood flow through small capillaries). Biological samples are collected and processed within the established Biobank of the Internal Medicine V of the Heidelberg University Hospital.
Study: NCT06424353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoflas pulpectomy
Description: obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoflas pulpectomy
Description: obturation of root canals of primary molars with Endoflas using pressure seringe and lentilospiral files
Study: NCT04852822

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT04301284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-1883
Description: 150 mg filled capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsules
Study: NCT04916249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tibetree Pain Relieving Plaster
Description: Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.
Study: NCT05824585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: DZD8586 treatment starting from 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586.
Study: NCT03229811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESRD education + conservative kidney management and ACP education
Description: Targeted conservative kidney management and advance care planning education delivered in person by trained healthcare providers
Study: NCT05732545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enteral nutrition program for patients with abdominal hypertension guided by abdominal pressure
Description: There are 4 aspects of intra-abdominal pressure monitoring, source control and treatment for the etiology of increased abdominal pressure, enteral nutrition program, enteral nutrition tolerance evaluation and treatment
Study: NCT06381583

Intervention type: DIAGNOSTIC_TEST
Intervention: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Description: A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)
Description: A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.
Study: NCT06031129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: The pharmacological attributes of Butorphanol, characterized by its mild impact on cardiopulmonary dynamics and demonstrated efficacy in attenuating mechanical traction-induced discomfort, culminate in an ameliorative effect on postoperative nausea and vomiting rates. Importantly, it substantively attenuates visceral postoperative pain. However, sedation can also cause dizziness, drowsiness, and other adverse reactions during recovery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline contain 0.9% NaCl sodium.
Study: NCT06505148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: administered alternatively with other drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administered alternatively with other drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: administered alternatively with other drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: administered alternatively with other drug
Study: NCT05129150

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Ultrasound examination with Tissue Pulsatility Imaging (TPI) TPI is a relatively simple, rapid and non-invasive ultrasound examination which consists of applying a standard ultrasound probe to the acoustic window of the temporal bone to first measure the velocity of the middle cerebral artery in Doppler mode and secondly the cerebral pulsatility (CP) of a region of approximately 10cm2 centred on the middle cerebral artery in B-Echo mode. After collecting the information, the TPI examination will be performed by MRRC staff specially trained in TPI by engineers. The duration of the examination is between 20 and 30 minutes, including hardware installation. Four 30-second PC acquisitions will be collected per examination, with the patient lying supine on the bed in the day hospital room, then one measurement every minute for 3 minutes after standing.
Study: NCT05366829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical development for the treatment of several human malignancies. Tislelizumab consolidation therapy after radiation therapy can capitalize on the immunomodulatory effect of radiotherapy and improve tumor responses and patient outcomes.
Study: NCT04674527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene
Description: Elemene injectable emulsion will be given for 80 mg/day in each 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance chemotherapy with TMZ will be administered at 150 mg/m2/day for 5 days in each 28-day cycle.
Study: NCT04214782

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
Description: AI Enabled Transvaginal Ultrasound diagnosis for ovarian cancer
Study: NCT04996719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune
Description: We will start the dose at 0.5mg capsule every other day for 2 weeks. If participants tolerate this dose and trough blood levels are (≤4ng/mL), the dose of rapamycin will be increased to 0.5mg daily for the duration of the study. If necessary, dose can remain at 0.5 mg every other day, depending on the trough level. To avoid immunosuppression, we will target lower dose of rapamycin, maintain lower trough serum levels (≤4ng/mL).